Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome
- Conditions
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 500
- Registration Number
- NCT06405178
- Locations
- 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Egypt
Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Sichuan Academy of Medical Sciences
- Target Recruit Count
- 70
- Registration Number
- NCT06398977
- Locations
- 🇨🇳
Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospita, Chengdu, Sichuan, China
Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet.
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Sun Jia
- Target Recruit Count
- 36
- Registration Number
- NCT06383832
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Zhujiang Hospital, Guangzhou, Guangdong, China
The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- The People's Hospital of Gaozhou
- Target Recruit Count
- 40
- Registration Number
- NCT06365541
- Locations
- 🇨🇳
The People's Hospital of Gaozhou, Maoming, Guangdong, China
Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Mohammed Mahmood Mohammed
- Target Recruit Count
- 40
- Registration Number
- NCT06326034
- Locations
- 🇮🇶
Mohammed Mahmood Mahmood, Baghdad, Iraq
CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 188
- Registration Number
- NCT06304857
- Locations
- 🇵🇱
4th Military Clinical Hospital with Polyclinic, Wrocław, Dolnośląskie, Poland
🇵🇱Lower Silesian Centre for Oncology, Lung Diseases and Hematology, Wrocław, Dolnośląskie, Poland
🇵🇱Military Medical Institute, Warsaw, Mazowieckie, Poland
Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes
- Conditions
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 80
- Registration Number
- NCT06286878
- Locations
- 🇧🇷
Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Anti-Diabetic Medications to Fight PD and LBD
- Conditions
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 12
- Registration Number
- NCT06263673
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 888
- Registration Number
- NCT06192108
- Locations
- 🇨🇳
The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇩🇪Diabetologische Schwerpunktpraxis und Praxis für Allgemeinmedizin Dr. Veronika Wenzl-Bauer u. Dr. Josef We -T, Rehlingen, Saarland, Germany
🇵🇱Ekamed, Lublin, Lubelskie, Poland
To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2023-11-27
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 240
- Registration Number
- NCT06147518
- Locations
- 🇮🇳
Dr Rakesh Kumar Jagdish, New Delhi, Delhi, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.